acquired Charles River Laboratories
’ Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient.
The Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form Quotient Clinical, a new strategic business unit within Quotient.
Quotient Clinical will have a workforce of approximately 160 medical, scientific, and clinical staff across the two facilities in Edinburgh and Nottingham. The new division will provide early development services to a broad range of pharmaceutical and biotechnology customers. Mark Egerton, formerly CEO of Pharmaceutical Profiles, will head the new business unit.
“The creation of Quotient Clinical represents the next step in expanding the range of specialized services we offer,” reports Paul Cowan, chairman and CEO of Quotient.
In addition to the Charles River facility and Pharmaceutical Profiles, Quotient has acquired HFL, BioDynamics Research, GR Micro, and Alba Bioscience since January 2007.